Lifecore Biomedical (LFCR) Competitors

Phibro Animal Health (NASDAQ:PAHC) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, community ranking, dividends and institutional ownership.

Which has more risk & volatility, PAHC or LFCR?

Phibro Animal Health has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, Lifecore Biomedical has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.

Which has better valuation & earnings, PAHC or LFCR?

Lifecore Biomedical has lower revenue, but higher earnings than Phibro Animal Health. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.19B	0.83	$2.42M	$0.78	31.42
Lifecore Biomedical	$130.31M	1.94	$12.01M	-$1.45	-4.71

Do institutionals and insiders believe in PAHC or LFCR?

99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by insiders. Comparatively, 32.2% of Lifecore Biomedical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Does the media prefer PAHC or LFCR?

In the previous week, Phibro Animal Health and Phibro Animal Health both had 4 articles in the media. Phibro Animal Health's average media sentiment score of 1.23 beat Lifecore Biomedical's score of 0.47 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lifecore Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is PAHC or LFCR more profitable?

Phibro Animal Health has a net margin of 1.75% compared to Lifecore Biomedical's net margin of -12.52%. Phibro Animal Health's return on equity of 25.35% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	1.75%	25.35%	6.21%
Lifecore Biomedical	-12.52%	-315.23%	-12.74%

Does the MarketBeat Community believe in PAHC or LFCR?

Phibro Animal Health received 313 more outperform votes than Lifecore Biomedical when rated by MarketBeat users. Likewise, 59.81% of users gave Phibro Animal Health an outperform vote while only 30.77% of users gave Lifecore Biomedical an outperform vote.

Company	Underperform	Outperform
Phibro Animal Health	Outperform Votes 317 59.81%	Underperform Votes 213 40.19%
Lifecore Biomedical	Outperform Votes 4 30.77%	Underperform Votes 9 69.23%

Do analysts recommend PAHC or LFCR?

Phibro Animal Health presently has a consensus target price of $20.00, indicating a potential downside of 18.40%. Lifecore Biomedical has a consensus target price of $8.00, indicating a potential upside of 17.13%. Given Lifecore Biomedical's stronger consensus rating and higher possible upside, analysts plainly believe Lifecore Biomedical is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Lifecore Biomedical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Phibro Animal Health beats Lifecore Biomedical on 12 of the 17 factors compared between the two stocks.